D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy

Cardiology

Volumn 117, Issue 1, 2010, Pages 31-36

  Sadanaga, Tsuneaki ^a   Kohsaka, Shun ^b   Ogawa, Satoshi ^c  

^a Ueki Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Atrial fibrillation; CHADS2 score; D dimer; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; D DIMER; INSULIN; LOOP DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SUBDURAL HEMATOMA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 77957112097     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319626     Document Type: Article

References (14)

1. Lip GYH, Lowe GDO, Rumley A, Dunn FG: Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73: 527-533.
2. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-638.
3. Van Walraven C, Hart RG, Singer DE, Lau-pacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441-2448.
4. Hart RG, Pearce LA, Aguilar MI: Meta-anal-ysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atri-al fibrillation. Ann Intern Med 2007; 146: 857-867.
5. Mahé I, Drouet L, Chassany O, Mazoyer E, Simoneau G, Knellwolf AL, Caulin C, Bergmann JF: D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation. Thrombosis Research 2002; 107:1-6.
6. Nozawa T, Inoue H, Hirai T, Iwasa A, Oku-mura K, Lee JD, Shimizu A, Hayano M, Yano K: D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006; 109: 59-65.
7. Vene N, Mavri A, Kosmelj K, Stegnar M: High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90: 1163-1172.
8. Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, Shimizu A, Hayano M, Yano K: Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. Int J Cardiol 2008; 126:316-321.
9. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870.
10. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby J V, Singer DE: Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685-2692.
11. Inoue H, Nozawa T, Hirai T, Iwasa A, Oku-mura K, Lee JD, Shimizu A, Hayano M, Yano K: Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70:651-656.
12. Sada naga T, Sadanaga M, Ogawa S: Ev idence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atria l f ibri l lation during ora l anticoagulant therapy. J Am Coll Cardiol 2010; 55: 2225-2231.
13. Ogawa S, Aizawa F, Atarashi H, Inoue H, Okumura K, Kamakura S, Kumagai K, Kore-tsune Y, Sugi K, Mitamura H, Yasaka M, Yamashita T: Guidelines for pharmacother-apy of atrial fibrillation (JCS 2008). Circ J 2008; 72(suppl):1581-1638 (in Japanese).
14. Yamaguchi T; for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke 2000; 31:817-821.